Carl Kraus Biography and Net Worth

Dr. Kraus joins the Aquestive team from Aceragen, where he served as Chief Medical Officer from October 2021 to April 2023. Prior to that, Dr. Kraus founded and served as the Chief Executive Officer of Arrevus from January 2017 until the sale to Aceragan in October 2021. He previously served as Chief Medical Officer of Ology Bioservices (formerly Nanotherapeutics), which was acquired by National Resilience.

Prior to joining the pharmaceutical industry, Dr. Kraus was a Medical Officer for the Center of Drug Evaluation and Research (“CDER”). Earlier in his career, he held inpatient and outpatient clinical appointments. Dr. Kraus earned his medical doctor degree from Washington University School of Medicine in St. Louis, MO, with post-graduate training in Internal Medicine (University of Chicago) and Infectious Diseases (National Institutes of Health).

What is Carl N. Kraus' net worth?: The estimated net worth of Carl N. Kraus is at least $1.10 million as of October 15th, 2025. Kraus owns 282,475 shares of Aquestive Therapeutics stock worth more than $1,096,003 as of March 24th. This net worth estimate does not reflect any other investments that Kraus may own. Learn More about Carl N. Kraus' net worth.
How old is Carl N. Kraus?: Kraus is currently 54 years old. There are 5 older executives and 3 younger executives at Aquestive Therapeutics. The oldest executive at Aquestive Therapeutics is Ms. Lori J. Braender BSBA, Esq., J.D., Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary, who is 68 years old. Learn More on Carl N. Kraus' age.
How do I contact Carl N. Kraus?: The corporate mailing address for Kraus and other Aquestive Therapeutics executives is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. Aquestive Therapeutics can also be reached via phone at (908) 941-1900 and via email at [email protected]. Learn More on Carl N. Kraus' contact information.
Has Carl N. Kraus been buying or selling shares of Aquestive Therapeutics?: Carl N. Kraus has not been actively trading shares of Aquestive Therapeutics over the course of the past ninety days. Most recently, Carl N. Kraus sold 20,272 shares of the business's stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $7.00, for a transaction totalling $141,904.00. Following the completion of the sale, the insider now directly owns 282,475 shares of the company's stock, valued at $1,977,325. Learn More on Carl N. Kraus' trading history.
Who are Aquestive Therapeutics' active insiders?: Aquestive Therapeutics' insider roster includes Daniel Barber (CEO), Peter Boyd (Insider), Lori Braender (Insider), Melina Cioffi (SVP), Ernest Jr (CFO), Cassie Jung (COO), Sherry Korczynski (Insider), Carl Kraus (Insider), and Alexander Schobel (Insider). Learn More on Aquestive Therapeutics' active insiders.
Are insiders buying or selling shares of Aquestive Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 672,460 shares worth more than $3,342,230.34. The most recent insider tranaction occured on March, 10th when insider Peter E Boyd sold 29,814 shares worth more than $124,324.38. Insiders at Aquestive Therapeutics own 8.4% of the company. Learn More about insider trades at Aquestive Therapeutics.
Information on this page was last updated on 3/10/2026.

Carl N. Kraus Insider Trading History at Aquestive Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/15/2025	Sell	20,272	$7.00	$141,904.00	282,475

Carl N. Kraus Buying and Selling Activity at Aquestive Therapeutics

Aquestive Therapeutics Company Overview

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Today's Range

Now: $3.88

$3.77

$3.91

50 Day Range

MA: $3.83

$2.95

$4.37

2 Week Range

Now: $3.88

$2.12

$7.55

Volume

1,537,372 shs

Average Volume

5,024,399 shs

Market Capitalization

$473.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Carl Kraus Biography and Net Worth

What is Carl N. Kraus' net worth?

How old is Carl N. Kraus?

How do I contact Carl N. Kraus?

Has Carl N. Kraus been buying or selling shares of Aquestive Therapeutics?

Who are Aquestive Therapeutics' active insiders?

Are insiders buying or selling shares of Aquestive Therapeutics?